Results from a phase III trial indicate that maintenance therapy with the PARP 
inhibitor niraparib is more effective than placebo in slowing the progression of 
recurrent platinum-sensitive ovarian cancer. Improved progression-free survival 
was seen regardless of the presence or absence of germline BRCA mutations, or of 
homologous recombination deficiency; however, patients who had these mutations 
or defective DNA repair did better.